RedShift Bioanalytics nets $20M in new financing

By The Science Advisory Board staff writers

October 19, 2021 -- RedShift BioAnalytics (RedShift Bio) has finalized a $20 million series E funding round.

The preferred stock financing round was led by Illumina Ventures, with participation by all of the company's current major investors. RedShiftBio said it would use the proceeds to fund additional commercial expansion and develop new applications and products.

The firm is developing platform technology to enable the measurement of previously undetectable structure changes in biomolecules.

Copyright © 2021

Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter